Baseline characteristics for patients with hematologic malignancy and prior VTE
| . | Overall (n = 204) . | Continuation (n = 132) . | Discontinuation (n = 72) . | P . |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 57 (48-65) | 56 (47-64) | 58 (49-65) | .34 |
| Female, n (%) | 77 (38) | 50 (38) | 27 (38) | 1.00 |
| White, n (%) | 187 (92) | 122 (92) | 65 (90) | .60 |
| Weight, kg | 84 (71-96) | 83 (71-96) | 86 (70-96) | .71 |
| Karnofsky Performance Status | 90 (80-90) | 90 (80-90) | 90 (80-90) | .55 |
| Hematologic malignancy, n (%) | ||||
| Plasma cell neoplasm | 57 (28) | 39 (30) | 18 (25) | .28 |
| Hodgkin lymphoma | 32 (16) | 20 (15) | 12 (17) | |
| Diffuse large B-cell lymphoma | 60 (29) | 33 (25) | 27 (38) | |
| Mantle cell lymphoma | 24 (12) | 19 (14) | 5 (7) | |
| Follicular lymphoma other NHL | 31 (15) | 21 (16) | 10 (14) | |
| Conditioning regimen, n (%) | ||||
| Melphalan | 68 (33) | 40 (30) | 18 (25) | .50 |
| BEAM | 58 (28) | 39 (30) | 29 (40) | |
| H-TBI/Cytoxan+/− VP16 | 47 (23) | 32 (24) | 15 (21) | |
| Other | 31 (15) | 21 (16) | 10 (14) | |
| Preconditioning laboratory tests | ||||
| WBC, 109/L | 4.6 (3.4-5.9) | 4.6 (3.4-5.9) | 4.6 (3.5-6.1) | .95 |
| Hemoglobin, g/dL | 11.3 (10.5-12.2) | 11.3 (10.5-12.3) | 11.4 (10.5-12.2) | .84 |
| Platelet, 103/μL | 181 (149-226) | 184 (149-229) | 176 (148-218) | .23 |
| Creatinine, mg/dL | 0.9 (0.8-1.0) | 0.9 (0.8-1.0) | 0.9 (0.7-1.1) | .77 |
| Bilirubin, mg/dL | 0.5 (0.4-0.6) | 0.5 (0.4-0.6) | 0.5 (0.4-0.7) | .76 |
| LDH, U/L | 179 (147-205) | 179 (152-205) | 173 (140-207) | .60 |
| PT, s | 13.0 (12.6-13.6) | 13.0 (12.5-13.6) | 13.0 (12.7-13.6) | .98 |
| Index VTE acuity, n (%) | ||||
| <1 mo | 72 (35) | 56 (42) | 16 (22) | <.01 |
| 1-3 mo | 69 (34) | 48 (37) | 20 (28) | |
| >3 mo | 63 (31) | 27 (20) | 36 (50) | |
| Index VTE type, n (%) | ||||
| CA-DVT only | 113 (55) | 68 (52) | 45 (63) | .14 |
| PE or DVT | 91 (45) | 64 (48) | 27 (38) | |
| Index VTE presentation, n (%) | ||||
| Symptomatic | 103 (50) | 66 (50) | 37 (51) | .88 |
| Incidental | 101 (50) | 66 (50) | 35 (49) | |
| Prior VTE history, n (%) | ||||
| Yes | 19 (9) | 15 (11) | 4 (6) | .21 |
| No | 185 (91) | 117 (89) | 68 (94) |
| . | Overall (n = 204) . | Continuation (n = 132) . | Discontinuation (n = 72) . | P . |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 57 (48-65) | 56 (47-64) | 58 (49-65) | .34 |
| Female, n (%) | 77 (38) | 50 (38) | 27 (38) | 1.00 |
| White, n (%) | 187 (92) | 122 (92) | 65 (90) | .60 |
| Weight, kg | 84 (71-96) | 83 (71-96) | 86 (70-96) | .71 |
| Karnofsky Performance Status | 90 (80-90) | 90 (80-90) | 90 (80-90) | .55 |
| Hematologic malignancy, n (%) | ||||
| Plasma cell neoplasm | 57 (28) | 39 (30) | 18 (25) | .28 |
| Hodgkin lymphoma | 32 (16) | 20 (15) | 12 (17) | |
| Diffuse large B-cell lymphoma | 60 (29) | 33 (25) | 27 (38) | |
| Mantle cell lymphoma | 24 (12) | 19 (14) | 5 (7) | |
| Follicular lymphoma other NHL | 31 (15) | 21 (16) | 10 (14) | |
| Conditioning regimen, n (%) | ||||
| Melphalan | 68 (33) | 40 (30) | 18 (25) | .50 |
| BEAM | 58 (28) | 39 (30) | 29 (40) | |
| H-TBI/Cytoxan+/− VP16 | 47 (23) | 32 (24) | 15 (21) | |
| Other | 31 (15) | 21 (16) | 10 (14) | |
| Preconditioning laboratory tests | ||||
| WBC, 109/L | 4.6 (3.4-5.9) | 4.6 (3.4-5.9) | 4.6 (3.5-6.1) | .95 |
| Hemoglobin, g/dL | 11.3 (10.5-12.2) | 11.3 (10.5-12.3) | 11.4 (10.5-12.2) | .84 |
| Platelet, 103/μL | 181 (149-226) | 184 (149-229) | 176 (148-218) | .23 |
| Creatinine, mg/dL | 0.9 (0.8-1.0) | 0.9 (0.8-1.0) | 0.9 (0.7-1.1) | .77 |
| Bilirubin, mg/dL | 0.5 (0.4-0.6) | 0.5 (0.4-0.6) | 0.5 (0.4-0.7) | .76 |
| LDH, U/L | 179 (147-205) | 179 (152-205) | 173 (140-207) | .60 |
| PT, s | 13.0 (12.6-13.6) | 13.0 (12.5-13.6) | 13.0 (12.7-13.6) | .98 |
| Index VTE acuity, n (%) | ||||
| <1 mo | 72 (35) | 56 (42) | 16 (22) | <.01 |
| 1-3 mo | 69 (34) | 48 (37) | 20 (28) | |
| >3 mo | 63 (31) | 27 (20) | 36 (50) | |
| Index VTE type, n (%) | ||||
| CA-DVT only | 113 (55) | 68 (52) | 45 (63) | .14 |
| PE or DVT | 91 (45) | 64 (48) | 27 (38) | |
| Index VTE presentation, n (%) | ||||
| Symptomatic | 103 (50) | 66 (50) | 37 (51) | .88 |
| Incidental | 101 (50) | 66 (50) | 35 (49) | |
| Prior VTE history, n (%) | ||||
| Yes | 19 (9) | 15 (11) | 4 (6) | .21 |
| No | 185 (91) | 117 (89) | 68 (94) |
Categorical variables were expressed as number and percentage, and continuous variables were expressed as median and interquartile range (IQR). Categorical and continuous variables were compared between the 2 treatment cohorts using Fisher’s exact test and Wilcoxon rank-sum test, respectively.
BEAM, carmustine, etoposide, cytarabine, melphalan; H-TBI, high-dose total body irradiation; LDH, lactate dehydrogenase; NHL, non-Hodgkin lymphoma; PT, prothrombin time; VP-16, etoposide; WBC, white blood cell count.